【导读】捷荣技术及其控股股东、实控人因涉嫌信息披露违法违规而被立案 2月27日，捷荣技术（002855）公告称，公司控股股东捷荣科技集团有限公司（以下简称捷荣集团）及实际控制人赵晓群，于2026年2月26日收到中国证监 会出具的《立案告知书》。因涉嫌信息披露违法违规，中国证监会决定对公司、捷荣集团及赵晓群立案。 据悉，赵晓群出生于1954年，是捷荣技术创始人、公司第一届至第三届董事会董事长，任职时长近10年。2024年1月，赵晓群退居二线，成为公司名誉董 事长。 2025年11月，时任公司董事长张守智因工作调整，申请辞去公司相关职务。72岁的赵晓群二度"出山"，担任捷荣技术董事长，其与公司现任总裁赵小毅为 姐弟关系。 从股权结构来看，赵晓群持有公司控股股东捷荣集团100%的股份，持有持股5%以上股东捷荣汇盈投资管理（香港）有限公司70.59%的股份。 公开资料显示，捷荣技术主要业务为向3C行业客户提供精密模具、精密结构件及高外观需求的硬件组件的设计、研发、制造和销售服务。 业绩方面，捷荣技术近年来深陷亏损，2021年—2024年累计亏损近8亿元，2025年公司预计净亏损额将进一步扩大。 1月31日，捷荣技术发 ...

Core Viewpoint - The annual "2025 Technology Wind and Cloud List" event was held on January 15, 2026, in Beijing, focusing on the theme "Inspiring New Intelligence, Embarking on a New Journey" [1][2]. Group 1: Company Insights - The CEO of Yupaodirect, Zhou Feng, announced that the platform has 120 million registered users and approximately 4 million daily active users [1][2]. Group 2: Industry Perspectives on AI - Zhou Feng discussed the current state of AI technology, emphasizing that robots cannot yet replace complex, multi-faceted jobs, particularly those requiring emotional intelligence, such as service roles [3][5]. - He highlighted that in industries like 3C manufacturing, most tasks are still performed by humans due to the intricate nature of components, which robots currently cannot handle with the required precision [3][5]. - Zhou noted that despite the emergence of AI, industries will continue to need software, hardware, and data, suggesting that jobs in these areas are less likely to be replaced by automation [3][5].

Core Viewpoint - Kosen Technology (603626.SH) announced the sale of its wholly-owned subsidiary, Kosen Medical, to Jiangsu Yaolingke Medical Technology Co., Ltd. for 915 million RMB, marking a significant strategic shift as the company exits the medical device sector [2] Group 1: Transaction Details - The transaction is based on an income approach, with the total equity value assessed at 913 million RMB as of September 30, 2025, reflecting an increase of 615 million RMB and a growth rate of 206.45% [2] - Kosen Technology expects to recognize approximately 600 million RMB in investment income from this divestiture, which will be recorded as non-recurring gains [2] - The deal is seen as a strategic acquisition for Yaolingke, enhancing its position in the precision medical device manufacturing sector [2] Group 2: Kosen Medical's Background - Kosen Medical has established itself as a competitive player in the medical device manufacturing industry, contributing to the high premium in the sale [7] - The company has collaborated with major clients like Medtronic, Zimmer, and Johnson & Johnson, providing critical components for various medical devices [9][10] - Despite its capabilities, Kosen Medical's revenue contribution has been low, accounting for about 10% of Kosen Technology's overall revenue, indicating its role as a supplementary business [6] Group 3: Reasons for Divestiture - Kosen Technology faced significant financial pressure, reporting cumulative losses of 873 million RMB from 2023 to the first three quarters of 2025, alongside high accounts receivable of 1.17 billion RMB [13] - The differing operational models between the consumer electronics and medical device sectors led to insufficient synergy, negatively impacting the efficiency of the core business [14] - The company aims to refocus on its core business in consumer electronics and energy storage, necessitating capital for overseas expansion projects [17] Group 4: Strategic Implications - The sale reflects broader challenges faced by manufacturing companies attempting to diversify into different sectors, particularly when operational demands and resource allocation become strained [26] - The entry of LYFE Capital into the medical manufacturing space signifies a shift towards asset acquisition in the global medical device sector, moving beyond previous focuses on R&D investments [27]